Introduction {#s1}
============

The oncoprotein c-Myc plays a pivotal role in multiple cellular processes, such as cell cycle progression, malignant transformation, differentiation suppression and apoptosis induction, predominantly through its transcription activity ([@bib49]; [@bib14]; [@bib54]; [@bib10]; [@bib44]; [@bib2]; [@bib29]; [@bib21]). Indeed, as a master transcriptional factor, c-Myc regulates the expression of approximately 10--15% of genes in the genome, including a variety of protein-coding genes ([@bib32]; [@bib39]; [@bib16]), such as *CDKN1A*, *CDKN2B*, *CCND1, CCND2, CDK4* and *E2F2* ([@bib1]).

Among c-Myc target genes, *CCND1* is of particular importance in cell cycle control and is characterized by the dramatic periodicity of the abundance of its protein product cyclin D1 throughout the cell cycle ([@bib51]). Cyclin D1 forms a complex with CDK4 or CDK6 and functions as a regulatory subunit whose activity is required for G1/S transition ([@bib51]; [@bib47]). Cyclin D1 also interacts with the tumor suppressor pRB1, which in turn positively regulates cyclin D1 expression ([@bib9]). Mutation, amplification and overexpression of *CCND1* are frequently observed in cancer and have been reported to contribute to tumorigenesis ([@bib56]; [@bib15]; [@bib38]). Cyclin D1 is a short-lived protein with a rapid turnover rate (\~24 min) due to degradation by the ubiquitin-proteasome system ([@bib13]; [@bib12]). While early studies showed that the Skp2 F-box protein is involved in cyclin D1 degradation ([@bib61]), a recent study has identified two additional F-box proteins that play important roles in targeting cyclin D1 for proteasome degradation ([@bib31]; [@bib41]).

c-Myc can upregulate or downregulate expression of cyclin D1 in a context-dependent manner. On the one hand, c-Myc, together with Max, a co-transcription factor, activates *CCND1* transcription through an E box located at −558 nt in its promoter ([@bib28]; [@bib62]; [@bib20]). On the other hand, simultaneous overexpression of c-Myc and ZO-2 enhances repression of the *CCND1* promoter through the E box in MDCK cells ([@bib19]). In addition, c-Myc has been reported to repress the cyclin DI promoter and antagonize USF-mediated transactivation in BALB/c-3T3, Rat6 and rat embryo fibroblasts ([@bib43]). In addition to c-Myc, multiple transcription factors, including AP-1, NF-κB, E2F and Oct-1, can bind to their respective *CCND1* promoters and regulate its expression ([@bib20]). *CCND1* can also be regulated epigenetically through histone modifications; GATA3 cooperates with PARP1 to regulate *CCND1* transcription by modulating histone H1 incorporation ([@bib50]). Moreover, post-transcriptional mechanisms are also involved in the regulation of *CCND1*, as exemplified by MYF5-mediated enhancement in *CCND1* mRNA translation, which contributes to early myogenesis ([@bib42]). Mutations in *CCND1* leading to stable truncated transcripts are associated with increased cell proliferation and shortened survival of cancer patients ([@bib56]).

Long noncoding RNAs (lncRNAs), which are defined as transcripts that are longer than 200 nucleotides and lack protein coding capacity, are emerging as important regulators of biological processes, including regulation of gene expression at multiple levels, such as chromatin remodeling, transcription, and post-transcriptional modulation ([@bib11]; [@bib23]; [@bib5]; [@bib57]). Genome-wide studies have shown that c-Myc transcriptionally regulates many lncRNA genes, such as *PVT1*, the CCAT family, and MYCLos, whereas a number of lncRNAs have been demonstrated to be important components of the c-Myc-mediated signaling network ([@bib6]; [@bib40]; [@bib33]; [@bib26]; [@bib27]). Nevertheless, whether lncRNAs participate in the regulation of *CCND1* remains to be fully studied.

Here, we report the isolation and characterization of the novel c-Myc regulated *LAST*, which acts as a *CCND1* mRNA stabilizer and without which *CCND1* mRNA becomes unstable and cell cycle arrest occurs in the G1 phase. Mechanistically, *LAST* cooperates with CNBP, a single-stranded DNA/RNA-binding factor, to bind to the 5' untranslated region of *CCND1* messenger RNA, possibly to protect against nuclease degradation. This report describes a model by which lncRNA stabilizes mRNA post-transcriptionally via 5'-end protection.

Results {#s2}
=======

Identification of *LAST*, a c-Myc-responsive long noncoding RNA that promotes cell proliferation {#s2-1}
------------------------------------------------------------------------------------------------

To identify novel functions of c-Myc-regulated long non-coding RNAs, doxycycline-treated or untreated P493-6 cells carrying a c-Myc tet-off system ([@bib25]) were used to analyze the lncRNA expression profile via long non-coding RNA microarray analysis *([Supplementary file 1](#supp1){ref-type="supplementary-material"}, GSE106916).* We selected five significantly c-Myc-downregulated lncRNAs (fold change above 8, P-value below 0.01) that were identified by the lncRNA microarray. Two of the five lncRNAs, namely, lncRNA-51 and lncRNA-52, along with CDK4 (positive control) were found to be downregulated when c-Myc expression was suppressed by doxycycline treatment ([Figure 1A](#fig1){ref-type="fig"}). Of these two c-Myc responsive lncRNAs, lncRNA-52 (RP11-660L16.2, ENST00000529369) was chosen for further investigation because knockdown of this lncRNA ([Figure 1B](#fig1){ref-type="fig"}) showed a *significant reduction in colony formation* ([Figure 1C and D](#fig1){ref-type="fig"}). lncRNA-52 is located approximately 1.8 Mb downstream of the *cyclin D1/CCND1* gene in a head-to-tail orientation ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). As will be shown in the following sections, this lncRNA is able to promote the stability of mRNA transcripts, including *CCND1* mRNA; we therefore named it *LAST* ([L]{.ul}ncRNA-[A]{.ul}ssisted [S]{.ul}tabilization of [T]{.ul}ranscripts).

![*LAST* is positively regulated by c-Myc.\
(**A**) P493-6 cells carrying a c-Myc tet-off system were treated with doxycycline (1 μg/mL) for 24 hr. The levels of five lncRNAs (lncRNA-5639,--51, −52,--5630 and −5690) and the positive control *CDK4* were assessed by real-time RT--PCR analysis. Data shown are the mean ± SD (n = 3; \*\*\*p\<0.001, two-tailed t-test). Cell lysates were also analyzed by western blotting with the indicated antibodies to ensure that gene expression was controlled by c-Myc. (**B**) HCT116 cells were infected with lentiviruses expressing control shRNA (sh-ctrl), shRNA-1,--2 against lncRNA-52 or shRNA-1,--2 against lncRNA-51, as indicated. The lentivirus-mediated gene knockdown efficiencies for both lncRNA-52 and lncRNA-51 were analyzed by real-time RT--PCR. Data shown are the mean ± SD (n = 3; \*\*p\<0.01, \*\*\*p\<0.001, two-tailed t-test). (**C**) Colonies of the above cells were stained with crystal violet and photographed after 14 days of incubation. (**D**) The number of colonies was counted and plotted in columns. (**E**) Total RNA from the indicated cell lines was subjected to northern blot analysis to determine the molecular size of *LAST*. (**F**) Single molecule RNA FISH detecting endogenous *LAST* molecules (green) in HCT116 and H1299. Chromosomal DNA (red) was stained with PI. (**G**) HCT116 and H1299 cells were fractionated into cytoplasmic and nuclear extracts. Total RNA extracted from each fraction was analyzed by real-time RT--PCR. Data shown are the mean ± SD (n = 3). Actin and U1 were used as markers for the cytoplasmic and nuclear fractions, respectively. (**H**) The *LAST* transcript copy numbers per cell in HAFF, IMR90, MCF10A, HCT116, MCF7 and H1299 cells were determined by absolute quantitative PCR (qPCR). Data shown are the mean ± SD (n = 3). (**I**) HCT116, H1299 and MCF10A cells were infected with lentiviruses expressing control shRNA or c-Myc shRNA. Ninety-six hours after infection, total RNA and cell lysates were analyzed by real-time RT-PCR and western blotting, respectively. Data shown are the mean ± SD (n = 3; \*\*p\<0.01, \*\*\*p\<0.001, two-tailed t-test). (**J**) HCT116, H1299 and MCF10A cells were transfected with empty vector or FLAG-c-Myc. Twenty-four hours after transfection, total RNA was extracted from these cells and subjected to real-time RT-PCR analysis. Data shown are the mean ± SD (n = 3; \*p\<0.05, \*\*p\<0.01, two-tailed t-test). Cell lysates were also analyzed by western blotting using the indicated antibodies. (**K**) Schematic representation of putative c-Myc binding sites around the *LAST* gene, predicted c-Myc binding fragments, qPCR-amplified fragments from the ChIP assay and fragments used in the luciferase reporter assay (upper panel). Lysates from HCT116 cells were subjected to the ChIP assay with a normal rabbit IgG or c-Myc antibody. ChIP products were amplified by qPCR with the indicated pairs of primers ([Table 1](#table1){ref-type="table"}). Data shown are the mean ± SD (n = 3; \*p\<0.05, two-tailed t-test) (lower panel). (**L**) Schematic diagram of the luciferase reporter systems constructed to assess *LAST* promoter activity. The indicated pGL3-based luciferase reporter constructs were generated to examine the transcriptional activities of two putative c-Myc binding sites, BS2 and BS3, in response to c-Myc induction. BS2M and BS3M indicate their corresponding mutant binding sites, which are written in black in the open boxes (upper panel). HCT116 cells were co-transfected with either FLAG-c-Myc or the control vector plus the indicated reporter constructs and Renilla luciferase plasmid. Twenty-four hours after transfection, reporter activity was measured and plotted after normalizing with respect to Renilla luciferase activity. Data shown are the mean ± SD (n = 3; \*p\<0.05, two-tailed t-test) (lower panel).\
10.7554/eLife.30433.006Figure 1---source data 1.Source data for [Figure 1A, B, D, G, H, I, J, K and L](#fig1){ref-type="fig"}.](elife-30433-fig1){#fig1}

To verify the existence of endogenous*LAST* and to determine its molecular size, northern blot analysis was performed. A band of approximately 700 nt in length was detected in both P493-6 and H1299 cells, but was absent in P493-6 cells treated with doxycycline, which suppresses c-Myc expression ([Figure 1E](#fig1){ref-type="fig"}). The apparent size of *LAST* was the same as predicted by the UCSC (University of California, Santa Cruz) Genome Browser, suggesting that *LAST* is a full-length transcript. To investigate the cellular compartment in which *LAST* is located, single molecule RNA fluorescent in situ hybridization (FISH) was performed in both HCT116 and H1299 cells. As shown in [Figure 1F](#fig1){ref-type="fig"}, *LAST* was predominantly localized in the cytosol. Cytosol localization of *LAST* was also confirmed by determining the levels of *LAST* in different sub-cellular fractions ([Figure 1G](#fig1){ref-type="fig"}). Moreover, the signal intensity of *LAST* was reduced in *LAST*-depleted cells ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}). It has been reported that lncRNAs are often present at relatively low copy numbers; hence, we measured the *LAST* transcript copy number per cell in various cell lines, including the normal cell lines HAFF, IMR90, and MCF10A and tumor cell lines HCT116, MCF7 and H1299. The *LAST* copy number was higher in tumor cells than in normal cells ([Figure 1H](#fig1){ref-type="fig"}).

Lentivirus-mediated gene knockdown of c-Myc decreased whereas ectopic expression of c-Myc increased *LAST* expression in HCT116, H1299 and MCF10A cells ([Figure 1I and J](#fig1){ref-type="fig"}). Furthermore, the levels of LAST and c-Myc appeared to be notably synchronous during cell cycle progression ([Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}). In particular, the c-Myc and *LAST* levels were decreased in G2/M (lane 2), followed by a rapid increase in the G1 phase (lane 3). These data suggest that *LAST* expression is positively regulated by c-Myc.

We next explored whether c-Myc regulates *LAST* expression at the transcriptional level. We first inspected the genomic sequence around the *LAST* gene using the JASPAR database ([@bib35]). Six putative c-Myc binding sites (BS1, BS2, BS3, BS4, BS5 and BS6) were identified ([Figure 1K](#fig1){ref-type="fig"}, upper panel). Furthermore, we analyzed the genomic sequence around the *LAST* gene using the ENCODE database. Three fragments (F1, F2 and F3) were predicted to be recognized by c-Myc ([Figure 1K](#fig1){ref-type="fig"}, upper panel). The chromatin immunoprecipitation (ChIP) assay determined the association of c-Myc with chromatin fragments corresponding to the BS2 and BS3 sites (within F2 fragment) among all examined fragments ([Figure 1K](#fig1){ref-type="fig"}, lower panel). We further evaluated whether BS2 and BS3 conferred c-Myc-dependent transcriptional activity. DNA fragments containing wild-type BS2 and BS3 or their corresponding mutant binding sites were inserted into the promoter region of a firefly luciferase reporter plasmid ([Figure 1L](#fig1){ref-type="fig"}, upper panel). Luciferase expression from the reporter containing an individual BS2 or BS3 site was indeed induced by ectopic expression of c-Myc ([Figure 1L](#fig1){ref-type="fig"}, lower panel). By contrast, mutant BS2M and BS3M sites showed no response to c-Myc induction ([Figure 1L](#fig1){ref-type="fig"}, lower panel). These data demonstrate that c-Myc transactivates *LAST*.

*LAST* promotes G1/S transition and upregulates *cyclin D1/CCND1* {#s2-2}
-----------------------------------------------------------------

Knockdown of *LAST* results in reduced colony formation ([Figure 1C](#fig1){ref-type="fig"}), indicating that *LAST* normally promotes cell proliferation. To examine how *LAST* affects cell growth, the *cell cycle phase* distribution was analyzed by *flow* cytometric *analysis*. Knockdown of *LAST* caused a decrease in the percentage of cells in the S and G2/M phases and an increase in the percentage of cells in the G1 phase ([Figure 2---figure supplement 1A and B](#fig2s1){ref-type="fig"}), indicating that *LAST* knockdown prevents cell passage from the G1 phase into S phase. As a result, *LAST* was shown to promote G1/S phase transition.

Cell cycle regulation is controlled by many factors. To define which factor(s) were involved in *LAST*-mediated regulation, the mRNA levels of G1-related cyclins and CDKs genes were selected for comparison in HCT116 cells before and after *LAST* gene knockdown. Among all of the mRNAs examined, only the *CCND1* mRNA level was significantly decreased ([Figure 2A](#fig2){ref-type="fig"}). Among all of the cyclins or CDKs examined, only cyclin D1 was shown to be downregulated when *LAST* was depleted ([Figure 2B](#fig2){ref-type="fig"}). The lncRNA *PVT1* is known to be a c-Myc regulated lncRNA that is involved in c-Myc stability and activity ([@bib6]). However, unlike *PVT1*, we found that *LAST,* which is also regulated by c-Myc ([Figure 1A](#fig1){ref-type="fig"}), does not affect c-Myc stability since knockdown of *LAST* did not change c-Myc expression at either the mRNA or protein levels ([Figure 2A and B](#fig2){ref-type="fig"}). The effect of *LAST* on cyclin D1/*CCND1* was further verified in normal HAFF cells and tumor H1299 and HCT116 cells. Depletion of *LAST* decreased whereas over-expression of *LAST* increased cyclin D1/*CCND1* expression at both the mRNA and protein levels ([Figure 2C and D](#fig2){ref-type="fig"}).

![*LAST* accelerates G1/S transition and upregulates *cyclin D1/CCND1*.\
(**A**) HCT116 cells were infected with lentiviruses expressing control shRNA, *LAST* shRNA-1 or −2. Ninety-six hours after infection, total RNA was extracted and the transcript levels for *LAST*, *CCND1*, *CCNE1*, *CDK2*, *CDK4* and *c-Myc* were analyzed by real-time RT-PCR. Data shown are the mean ± SD (n = 3; \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, two-tailed t-test). (**B**) Cell lysates prepared as described above ([Figure 2A](#fig2){ref-type="fig"}) were analyzed by western blotting to examine GAPDH, cyclin D1, cyclin E1, Actin, CDK2, CDK4 and c-Myc expression. (**C**) HAFF and H1299 cells were infected with lentiviruses expressing control shRNA or *LAST* shRNA. Ninety-six hours after infection, total RNA was analyzed by real-time RT-PCR to detect the level of *LAST* to determine its knockdown efficiency (lower panel). Total RNA was also analyzed by real-time RT-PCR to detect the level of *CCND1* mRNA and by western blotting to examine the cyclin D1 protein level (upper panel). Data shown are the mean ± SD (n = 3; \*p\<0.05, \*\*p\<0.01). (**D**) HCT116, H1299 and HAFF cells were infected with lentiviruses expressing control RNA or *LAST*. Ninety-six hours after infection, total RNA was analyzed by real-time RT-PCR to detect successful expression of *LAST* (lower panel). Total RNA was also analyzed by real-time RT-PCR to detect the level of *CCND1* mRNA and by western blotting to examine the cyclin D1 protein level (upper panel). Data shown are the mean ± SD (n = 3; \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, two-tailed t-test).\
10.7554/eLife.30433.010Figure 2---source data 1.Source data for [Figure 2A, C and D](#fig2){ref-type="fig"}.](elife-30433-fig2){#fig2}

To test if the function of LAST is mediated through an effect on the adjacent genes, we checked the shRNA-mediated *LAST* knockdown effect on the two adjacent genes *DHCR7* and *NADSYN1* ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}) and found that *LAST* showed no effect on either the mRNA or protein levels of those two genes ([Figure 2---figure supplement 1C](#fig2s1){ref-type="fig"}). Furthermore, we introduced shRNA-resistant *LAST* into *LAST* depleted cells, and as shown in [Figure 2---figure supplement 1D and E](#fig2s1){ref-type="fig"}, both the *CCND1* mRNA and protein levels were rescued. This result excludes off-target effects of *LAST* shRNA knockdown.

*LAST* cooperates with CNBP to regulate *CCND1* mRNA stability {#s2-3}
--------------------------------------------------------------

To investigate how *LAST* affects the *CCND1* mRNA level, we first examined whether *LAST* regulates the *CCND1* mRNA transcription process. The levels of both *CCND1* pre-mRNA and mature mRNA were examined by primers against *CCND1* mRNA intron- or exon-specific regions in HCT116 cells treated with and without *LAST* knockdown. The levels of *CCND1* pre-mRNA containing four intronic regions were found to remain unaltered between control and *LAST* knockdown cells, whereas the levels of mature spliced *CCND1* mRNA containing 5'UTR, CDS (coding sequences) and 3'UTR regions were greatly reduced upon *LAST* depletion ([Figure 3---figure supplement 1A and B](#fig3s1){ref-type="fig"}). These results suggest that *LAST* may post-transcriptionally regulate *CCND1* mRNA. To evaluate the effect of *LAST* on the stability of *CCND1* mRNA, HCT116 cells were treated with actinomycin D, which measures the decay of pre-existing mRNA. Knockdown of *LAST* resulted in a decrease of the half-life of *CCND1* mRNA from 5 hr to 3 hr ([Figure 3A](#fig3){ref-type="fig"}), whereas over-expression of *LAST* increased its half-life from 5 hr to 9 hr ([Figure 3B](#fig3){ref-type="fig"}), indicating that *LAST* stabilizes *CCND1* mRNA. To determine whether *LAST* interacts with *CCND1* mRNA, we performed a biotinylated oligonucleotide pull-down assay, and as shown in [Figure 3C](#fig3){ref-type="fig"}, endogenous *CCND1* mRNA but not *CCNB1* mRNA co-precipitated with *LAST*, indicating an association between *LAST* and *CCND1* mRNA. However, by careful inspection, we found there was no complementary base pairing between *LAST* and *CCND1* mRNA. We therefore hypothesized that some protein(s) may mediate this binding. Proteins pulled down by *LAST* were separated by SDS PAGE, and a unique band with a molecular weight of approximately 20 kDa was revealed and identified as CNBP by mass spectrometry ([Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}, left panel). CNBP has a preference for binding single-stranded DNA and RNA ([@bib17]) and has been reported to function in the translation of ornithine decarboxylase mRNA ([@bib48]). To validate the MS Spectro result, we performed a *LAST* pull-down assay. A biotin-labeled antisense DNA probe against *LAST* pulled down CNBP, but not cyclin D1 ([Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}, right panel). To further demonstrate that CNBP can bridge *CCND1* mRNA and *LAST*, we first pulled down *CCND1* mRNA using a biotinylated antisense DNA probe as bait; both CNBP and *LAST* were coprecipitated ([Figure 3D](#fig3){ref-type="fig"}). The RIP assay further concluded that CNBP interacts with both *CCND1* mRNA and *LAST* ([Figure 3E](#fig3){ref-type="fig"}). These data demonstrate that CNBP acts as a mediator for *LAST* and *CCND1* mRNA binding. As shown in [Figure 3F](#fig3){ref-type="fig"}, CNBP knockdown in HCT116 led to a decrease in both the mRNA and protein levels of *cyclin D1/CCND1*. The effect of CNBP on the stability of *CCND1* mRNA was evaluated in HCT116 cells treated with actinomycin D. The half-life of *CCND1* mRNA was reduced from 5 hr to 3 hr as CNBP was depleted ([Figure 3G](#fig3){ref-type="fig"}), further demonstrating that CNBP prolongs the *CCND1* mRNA half-life. Because CNBP predominantly resides in the cytosol, we investigated whether the association of *CCND1* mRNA with *LAST* via CNBP only occurs in the cytosol. Using a *LAST* and *CCND1* mRNA pull-down assay, we found that CNBP was co-precipitated by either *LAST* or *CCND1* mRNA in the cytoplasm, but not the nucleus ([Figure 3---figure supplement 1D](#fig3s1){ref-type="fig"}). HNRNPK was used as a nuclear marker. Moreover, knockdown of CNBP was shown to result in decreased levels of *CCND1* mRNA ([Figure 3F](#fig3){ref-type="fig"}). Further investigation revealed that knockdown of CNBP affected the level of mature *CCND1* mRNA, but not unspliced *CCND1* pre-mRNA, indicating that the protective role of CNBP in mature *CCND1* mRNA stability occurred in the cytosol since nuclear unspliced *CCND1* pre-mRNA was not affected when CNBP was silenced ([Figure 3---figure supplement 1E](#fig3s1){ref-type="fig"}). To further confirm that *LAST* affects *CCND1* mRNA stability through CNBP, we knocked down CNBP in HCT116 cells. As shown in [Figure 3---figure supplement 1F](#fig3s1){ref-type="fig"}, the increased expression of *CCND1* mRNA caused by over-expression of *LAST* was diminished when CNBP was depleted (lanes 2 vs. 4). Thus, our hypothesis is that *LAST* affects *CCND1* mRNA via CNBP. Knockdown of *LAST* resulted in no change in CNBP at either the RNA or protein levels ([Figure 3H](#fig3){ref-type="fig"}), which suggests that *LAST* affects *CCND1* mRNA not according to the quantity of CNBP, but rather by the association of CNBP and *CCND1* mRNA. It was therefore expected that knockdown of CNBP would reduce the association between *LAST* and *CCND1* mRNA. This was indeed the case. An RNA pull-down experiment was performed starting with the same amount of *CCND1* mRNA, and less *LAST* was co-precipitated as CNBP was depleted ([Figure 3I](#fig3){ref-type="fig"}). Similarly, when we pulled down the same amount of *CCND1* mRNA, less co-precipitated CNBP was detected as *LAST* was silenced. As a negative control, the RNA-binding protein HuR remained unchanged after *LAST* was knocked down ([Figure 3J](#fig3){ref-type="fig"}). These data suggest that *LAST* cooperates with CNBP to regulate *CCND1* mRNA stability.

![*LAST* stabilizes *CCND1* mRNA via CNBP.\
(**A**) HCT116 cells expressing control shRNA, *LAST* shRNA-1 or −2 were treated with actinomycin D (1 μg/mL) for the indicated periods of time. Total RNA was purified and then analyzed by real-time RT-PCR to examine the mRNA half-life of *CCND1*. Data shown are the mean ± SD (n = 3; \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, two-tailed t-test). (**B**) HCT116 cells expressing control RNA or *LAST* were treated with actinomycin D (1 μg/mL) for the indicated periods of time. Total RNA was extracted and then analyzed by real-time RT-PCR to examine the mRNA half-life of *CCND1*. Data shown are the mean ± SD (n = 3; \*p\<0.05, \*\*p\<0.01, two-tailed t-test). (**C**) HCT116 cell lysates were incubated with in vitro synthesized biotin-labeled sense or antisense DNA probes against *LAST* for the biotinylated oligonucleotide pull-down assay. The precipitates from the pull-down were analyzed by real-time RT-PCR to detect the interacting mRNAs. Data shown are the mean ± SD (n = 3; \*\*p\<0.01, \*\*\*p\<0.001, two-tailed t-test). (**D**) HCT116 cell lysates were incubated with in vitro synthesized biotin-labeled sense or antisense DNA probes against *CCND1* mRNA for the biotin pull-down assay. The precipitates from the pull-down underwent real-time RT-PCR and western blot analyses to examine the levels of indicated RNAs and protein CNBP, respectively. Data shown are the mean ± SD (n = 3; \*p\<0.05, \*\*p\<0.01, two-tailed t-test). (**E**) HCT116 cell lysates were immunoprecipitated with an antibody against CNBP or normal mouse IgG~2a~. Precipitated samples were analyzed by western blotting to ensure successful precipitation of CNBP and by real-time RT-PCR to detect the indicated coprecipitated RNAs. Data shown are the mean ± SD (n = 3; \*p\<0.05, \*\*p\<0.01, two-tailed t-test). (**F**) HCT116 cells were infected with lentiviruses expressing control shRNA or *CNBP* shRNA. Ninety-six hours after infection, total RNA was subjected to real-time RT-PCR to compare the levels of *CCND1* mRNA. Data shown are the mean ± SD (n = 3; \*p\<0.05, \*\*p\<0.01, two-tailed t-test). Cell lysates were also analyzed by western blotting with the indicated antibodies. (**G**) HCT116 cells expressing control shRNA or *CNBP* shRNA were treated with actinomycin D (1 μg/mL) for the indicated periods of time. Total RNA was then analyzed by real-time RT-PCR to examine the mRNA half-life of *CCND1*. Data shown are the mean ± SD (n = 3; \*p\<0.05, \*\*p\<0.01, two-tailed t-test). (**H**) HCT116 cells were infected with lentiviruses expressing control shRNA, *LAST* shRNA-1 or −2. Ninety-six hours after infection, total RNA was subjected to real-time RT-PCR to compare the levels of *CNBP*. Data shown are the mean ± SD (n = 3; \*\*p\<0.01, two-tailed t-test). Cell lysates were also analyzed by western blotting to examine actin and CNBP expression. (**I**) Cell lysates of HCT116 cells expressing control shRNA or *CNBP* shRNA were incubated separately with in vitro synthesized biotin-labeled sense or antisense DNA probes against *CCND1* mRNA for the biotinylated oligonucleotide pull-down assay. The pull-down products were subjected to real-time RT-PCR analysis to examine the indicated RNA levels. Cell lysates from HCT116 treated with or without *CNBP* shRNA knockdown were subjected to western blotting to ensure knockdown of CNBP. Data shown are the mean ± SD (n = 3; \*p\<0.05, \*\*\*p\<0.001, two-tailed t-test). (**J**) Cell lysates of HCT116 cells expressing control shRNA or *LAST* shRNA-1 were incubated with in vitro synthesized biotin-labeled sense or antisense DNA probes against *CCND1* mRNA for the biotin pull-down assay, followed by real-time RT-PCR analysis to examine the indicated RNA levels. Pull-down products were also subjected to western blotting with the indicated antibodies and real-time RT-PCR. Data shown are the mean ± SD (n = 3; \*\*p\<0.01, two-tailed t-test).\
10.7554/eLife.30433.014Figure 3---source data 1.Source data for [Figure 3A, B, C, D, E, F, G, H, I and J](#fig3){ref-type="fig"}.](elife-30433-fig3){#fig3}

Both *LAST* and *CCND1* mRNA bind to CNBP through their G-rich motifs {#s2-4}
---------------------------------------------------------------------

To describe a detailed CNBP, *LAST* and *CCND1* mRNA binding mechanism, we mapped the *LAST* and CNBP binding sites on *CCND1* mRNA by RNA pull-down using different in vitro biotin-labeled fragments ([Figure 4A](#fig4){ref-type="fig"}, upper panel). We found that the 5'UTR but not 3'UTR-1,--2 and −3 of *CCND1* mRNA was able to bind *LAST* and CNBP ([Figure 4A and B](#fig4){ref-type="fig"}), indicating that *LAST* and CNBP bind to the 5' region of *CCND1* mRNA. To further determine whether *LAST* and CNBP bind to the *CCND1* mRNA 5'UTR to enhance its stability, two *CCND1* expression constructs were generated, as shown in [Figure 4---figure supplement 1A and B](#fig4s1){ref-type="fig"}. One construct contained the *CCND1* coding region (CD) plus the 5'UTR and the other contained the CD alone. The expression plasmid plus *LAST* and CNBP or plasmid alone was individually transfected into 293T cells. Actinomycin D was added to measure the mRNA decay rate. The half-life of ectopically expressed *CCND1* mRNA lacking the 5'UTR was not altered by the presence or absence of *LAST* and CNBP ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}). By contrast, the half-life of *CCND1* mRNA bearing 5\'-UTRs was extended from 4 hr in the absence of *LAST* and CNBP to 9 hr in the presence of *LAST* and CNBP, indicating that *LAST* and CNBP enhanced *CCND1* mRNA stability via its 5'UTR ([Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}). In addition, we performed CNBP RIP sequencing, and an enrichment peak at the *CCND1* 5'UTR was observed ([Figure 4---figure supplement 1C](#fig4s1){ref-type="fig"}). This was consistent with the previous conclusion from [Figure 4B](#fig4){ref-type="fig"}. Thus, our hypothesis is that CNBP binds both *CCND1* mRNA and *LAST*. We again examined whether *LAST*, the 5\'-UTR of *CCND1* mRNA and CNBP form a ternary complex by using a sequential immuno-precipitation assay ([Figure 4---figure supplement 2A](#fig4s2){ref-type="fig"}). By using an anti-FLAG antibody against FLAG--CNBP, both the biotin-labeled 5\'-UTR of *CCND1* mRNA and *LAST* were pulled down in an initial immunoprecipitation assay ([Figure 4C](#fig4){ref-type="fig"}, panel 1 and 3). The immunocomplexes were eluted and were subsequently precipitated by streptavidin sepharose beads against the biotin-labeled 5\'-UTR of *CCND1* mRNA. *LAST* and CNBP were present in the streptavidin-biotin precipitates ([Figure 4C](#fig4){ref-type="fig"}, panel 5 and 6), indicating that these three components indeed form a ternary complex.

![CNBP binds to *LAST* and *CCND1* mRNA via their G-rich motifs.\
(**A**) Schematic illustration showing different parts, including the 5'UTR, CDS, 3'UTR-1, 3'UTR-2 and 3'UTR-3, in *CCND1* mRNA (upper panel). HCT116 cell lysates were incubated with in vitro synthesized biotin-labeled *CCND1* 5'UTR as well as 3'UTR-1,--2, and −3 (upper panel), followed by RNA pull-down. Cell lysates incubated with no RNA were used as negative controls. Pull-down products were subjected to real-time RT-PCR. Data shown are the mean ± SD (n = 3; \*\*p\<0.01, two-tailed t-test) (lower panel). (**B**) The pull-down products from above were analyzed by western blotting with the indicated antibodies. (**C**) In-vitro synthetic biotin-labeled *CCND1* 5'UTR and unlabeled *LAST* plus Flag-CNBP were incubated for 3 hr at 4°C. The mixtures were first immunoprecipitated with M2 beads, followed by elution with 3 × FLAG peptides. Ten percent of the eluent was analyzed by western blotting or RT-PCR. The rest of the eluent was further immunoprecipitated with streptavidin beads. The immunoprecipitates were then washed. After elution, 10% of the eluent was analyzed by western blotting. Ninety percent of the eluent was used for real-time RT-PCR analysis. (**D**) A schematic illustration of two G-rich regions in the *CCND1* 5'UTR. Electrophoretic mobility shift assay (EMSA) was performed to detect the CNBP binding activity to its targeted G-rich region 1 and 2. (**E**) A schematic illustration of six G-rich regions in *LAST*. An electrophoretic mobility shift assay (EMSA) was performed to detect the CNBP binding activity to its targeted G-rich motif A, B, C, D, E and F. (**F**) HCT116 cells were infected with lentiviruses expressing either control RNA; wild-type *LAST; LAST* individually mutated at G-rich-A, G-rich-C, G-rich-D and G-rich-F sites; or LAST mutated at the four G-rich-A, C, D and F sites combined. Ninety-six hours after infection, total RNA was analyzed by real-time RT-PCR to detect the successful expression levels of *LAST* or mutant *LAST*. Data shown are the mean ± SD (n = 3; \*\*p\<0.01, two-tailed t-test). (**G**) Total RNA of HCT116 cells separately expressing exogenous control RNA; wild-type *LAST; LAST* with a single mutation at G-rich-A, G-rich-C, G-rich-D or G-rich-D; and *LAST* with four mutations combined were analyzed by real-time RT-PCR to detect the mRNA level of *CCND1*. Data shown are the mean ± SD (n = 3; \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, two-tailed t-test).\
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CNBP prefers to bind G-rich motifs, especially the GGAG core ([@bib3]; [@bib4]). We checked the proportion of G-rich motifs in all of the peak sequences from the CNBP RIP samples. Nearly sixty percent of the CNBP enriched sequences contained the GGAG motif, and more than ninety percent of the peak sequences contained a GGR motif ([Figure 4---figure supplement 2B](#fig4s2){ref-type="fig"}). To assess the possible CNBP binding sites on *LAST* and *CCND1* mRNA, the bioinformatics software tool QGRS Mapper was utilized ([@bib24]). Two G-rich sequences containing a GGAG core in the 5'UTR of *CCND1* mRNA were identified ([Figure 4D](#fig4){ref-type="fig"}, upper part). An electrophoretic mobility shift assay (EMSA) was performed, and the results showed that G-rich-1 and G-rich-2 in the *CCND1* 5'UTR were responsible for the binding of CNBP ([Figure 4D](#fig4){ref-type="fig"}, lower part). Among the six predicted G-rich sequences (G-rich-A to F) found in *LAST* ([Figure 4E](#fig4){ref-type="fig"}, upper part), four G-rich sequences (G-rich-A, C, D and F) were found to contain a GGAG core. G-rich-A, C, D and F from *LAST* were able to bind CNBP, whereas neither G-rich-B nor G-rich-E was able to bind CNBP ([Figure 4E](#fig4){ref-type="fig"}, lower part). Thus, CNBP only interacted with G-rich sequences that contained the GGAG core, but not those lacking the GGAG core. These data suggest that both *CCND1* and *LAST* interact with CNBP via their G-rich motifs containing the GGAG core. Four G-rich regions (A, C, D and F) were mutated from GGAG to UUUU with either a single mutation or four combined mutations in *LAST*. We found that over-expression of *LAST* containing only one site mutation led to an increase in the *CCND1* mRNA level, whereas over-expression of *LAST* containing four G-rich site mutations nullified its effect on the *CCND1* mRNA level ([Figure 4F and G](#fig4){ref-type="fig"}). This result indicates that the effect of *LAST* on *CCND1* stability requires at least one of the four functional G-rich motifs. To define which domain of CNBP is responsible for binding *LAST* and the *CCND1* 5'UTR, a biotin-labeled RNA pull-down assay and deletion mapping were performed. According to the web site InterPro ([@bib22]), CNBP can be divided into four structural domains based on its zinc-finger arrangement ([Figure 4---figure supplement 2C](#fig4s2){ref-type="fig"}). As shown in [Figure 4---figure supplement 2C](#fig4s2){ref-type="fig"}, we concluded that *LAST* binds to the CNBP fragment corresponding to amino acids 92--134 (domain 3), whereas the *CCND1* 5'UTR binds to the CNBP fragment corresponding to amino acids 29--134 (domain 2 + domain 3) ([Figure 4---figure supplement 2C](#fig4s2){ref-type="fig"}). Determination of the exact mechanism of these associations requires further investigation.

In addition to *CCND1*, *LAST* regulates the stability of other mRNAs {#s2-5}
---------------------------------------------------------------------

To globally identify transcripts that simultaneously meet the following requirements: (i) transcripts are downregulated by *LAST* knockdown and (ii) transcripts are able to bind to CNBP, we assembled two unbiased transcriptome profiles using *LAST* knockdown mRNA-seq and CNBP RIP-seq in HCT116 cells. The intersection of these two arrays is shown in [Figure 5A](#fig5){ref-type="fig"}, and 225 overlapping genes were found ([Supplementary file 2](#supp2){ref-type="supplementary-material"}). We further narrowed this list down to 75 genes ([Supplementary file 2](#supp2){ref-type="supplementary-material"}, bold part) based on the criteria that CNBP-enriched genes must be 4-fold above the input control level. Three mRNAs, namely, *SOX9*, *NFE2L1* and *PDF,* were also likely to be regulated by *LAST*, as knockdown of *LAST* led to a decrease in their levels ([Figure 5B](#fig5){ref-type="fig"}). Experimental verification showed that knockdown of *LAST* decreased ([Figure 5C](#fig5){ref-type="fig"}) whereas over-expression of *LAST* increased their half-lives ([Figure 5D](#fig5){ref-type="fig"}). In addition, CNBP deletion led to a decrease in the mRNA levels of *SOX9*, *NFE2L1* and *PDF* ([Figure 5E and F](#fig5){ref-type="fig"}). These data suggest that *LAST*, together with CNBP, can regulate the stabilization of additional mRNAs, such as *SOX9*, *NFE2L1* and *PDF*.

![The synergistic effect of *LAST* and CNBP on mRNA expression.\
(**A**) Venn diagram represents 225 overlapping transcripts ([Supplementary file 2](#supp2){ref-type="supplementary-material"}) obtained from *LAST* RNA-seq (red) and CNBP RIP-seq (violet). (**B**) Heatmap showing that *SOX9*, *NFE2L1*, *PDF* and *CCND1* are not only decreased upon *LAST* knockdown but also enriched by CNBP. (**C**) HCT116 cells expressing control shRNA or *LAST* shRNA-1 were treated with actinomycin D (1 μg/mL) for the indicated periods of time. Total RNAs were extracted and then analyzed by real-time RT-PCR to examine the mRNA half-life of *SOX9*, *NFE2L1* and *PDF*. Data shown are the mean ± SD (n = 6; \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, two-tailed t-test). (**D**) HCT116 cells expressing control RNA or *LAST* were treated with actinomycin D (1 μg/mL) for the indicated periods of time. Total RNAs were extracted and then analyzed by real-time RT-PCR to examine the mRNA half-life of *SOX9*, *NFE2L1* and *PDF*. (**E**) HCT116 cells were infected with lentiviruses expressing control shRNA or *CNBP* shRNA. Ninety-six hours later, cell lysates were subjected to western blotting to detect the CNBP knockdown efficiency. (**F**) HCT116 cells were infected with lentiviruses expressing control shRNA or *CNBP* shRNA. Ninety-six hours after injection, total RNA was analyzed by real-time RT-PCR with the indicated primers. Data shown are the mean ± SD (n = 3; \*\*\*p\<0.001, two-tailed t-test).\
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*LAST* promotes tumorigenesis {#s2-6}
-----------------------------

To further determine whether *LAST* regulates tumorigenesis, we used a xenograft mouse model. HCT116 cells stably expressing exogenous *LAST* or *LAST* shRNA-1 were injected subcutaneously into the dorsal flanks of nude mice (left (control) and right (treated), n = 7 for each group). According to animal care and enforcement, mice were sacrificed when the largest subcutaneous tumor mass on one flank was close to one cubic centimeter. Tumors expressing control shRNA or *LAST* shRNA-1 were excised after 6 weeks, and tumors expressing control RNA or *LAST* were excised after 3 weeks. Mice were sacrificed and tumors were excised. Knockdown of *LAST* decreased the tumorigenicity of HCT116 cells ([Figure 6A and B](#fig6){ref-type="fig"}). By contrast, induction of *LAST* promoted HCT116 cell tumorigenicity ([Figure 6C and D](#fig6){ref-type="fig"}). Furthermore, based on the TCGA dataset ([@bib55]), we found that the *LAST* expression levels were higher in tumor tissues than normal tissues, including the human bladder, breast, colorectal, esophagus, head and neck, kidney, liver, lung, prostate and stomach. In addition, the *CCND1* expression levels were higher in tumor tissues than in normal tissues, including the human bladder, breast, cervix, bile duct, colorectal, esophagus, head and neck, kidney, pancreas, stomach and uterus. In conclusion, both the *LAST* and *CCND1* expression levels were higher in most tumor tissues than in their normal counterparts ([Figure 6E and F](#fig6){ref-type="fig"}, [Figure 6---figure supplements 1](#fig6s1){ref-type="fig"} and [2](#fig6s2){ref-type="fig"}). The above results suggest that *LAST* promotes tumorigenesis.

![*LAST* promotes tumorigenesis.\
(**A**) A total of 3 × 10^6^ HCT116 cells expressing either control shRNA or *LAST* shRNA-1 were individually injected subcutaneously into the flanks of nude mice (n = 7 for each group) as indicated. Representative photographs of xenograft tumors in situ were taken 6 weeks after injection. (**B**) Tumors of the above nude mice ([Figure 6A](#fig6){ref-type="fig"}) were also selected to be weighed. Data shown are the mean ± SD (n = 7; \*\*\*p\<0.001, two-tailed t-test). (**C**) A total of 3 × 10^6^ HCT116 cells expressing either control RNA or *LAST* were individually injected subcutaneously into the flanks of nude mice (n = 7 for each group) as indicated. Representative photographs of xenograft tumors in situ were taken 3 weeks after injection. (**D**) Tumors of the above nude mice ([Figure 6C](#fig6){ref-type="fig"}) were selected and weighed. Data shown are the mean ± SD (n = 7; \*\*\*p\<0.001, two-tailed t-test). (**E**) Data for the *LAST* and *CCND1* expression levels in COAD (colon adenocarcinoma) tumor and normal tissues were downloaded from the TCGA dataset. Box plots showing differential expression of *LAST* and *CCND1* between normal (n = 41) and tumor (n = 454) samples. Statistical analysis was performed using the two-tailed t-test (\*\*\*p\<0.001). (**F**) Data for *LAST* and *CCND1* expression levels in READ (rectum adenocarcinoma) tumor and normal tissues were downloaded from the TCGA dataset. Box plots showing the differential expression of *LAST* and *CCND1* between normal (n = 10) and tumor (n = 165) samples. Statistical analysis was performed using the two-tailed t-test (\*\*\*p\<0.001). (**G**) Pathway analysis of differentially downregulated genes (log2 (fold change) below - 0.58 in RNA-seq) in HCT116 with and without *LAST* knockdown. The top 10 significant pathways with enrichment scores are shown. (**H**) A schematic illustration of the proposed model depicting the role of c-Myc-induced *LAST* in regulating *CCND1* mRNA stability via CNBP. (**I**) Gene homology analysis of *LAST* in human, chimp, gorilla, rhesus, mouse, rabbit, dog, chicken and zebrafish.\
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To assess the impact of *LAST* deficiency on gene expression in HTC116, we performed unbiased transcriptome profiling using RNA-seq in HCT116 cells. The absence of *LAST* downregulated expression of 667 genes (log2 (fold change) below - 0.58) ([Supplementary file 3](#supp3){ref-type="supplementary-material"}). We then performed pathway analysis in those genes and found the top 10 significant pathways that were significantly associated with 667 differentially expressed genes. Among these 10 pathways, the majority were associated with tumorigenesis ([Figure 6G](#fig6){ref-type="fig"}).

Discussion {#s3}
==========

Cyclin D1 is a critical regulator of CDK kinase, which regulates cell cycle progression at the G1 to S-phase transition. Pre- or mature *CCND1* mRNA is regulated at different hierarchical levels bymultiple protein factors. Multiple classical transcriptional factors, such as c-Myc, E2F1, OCT1，RELA and c-Jun, have been reported to modulate *CCND1* at the transcriptional level ([@bib20]). Epigenetic and post-transcriptional mechanisms are also involved in the regulation of *cyclin D1/CCND1* (16, 29, 30). Moreover, Pitx2 and HuR, which belong to the same ribonucleoprotein complex, also control the decay rate of *CCND1* mRNA ([@bib18]). However, whether lncRNA(s) is (are) involved in the regulation of *CCND1* mRNA stability remains largely unaddressed. Very recently, NcRNA~CCND1~ was reported to negatively regulate *CCND1* transcription by recruiting TLS to the *CCND1* promoter ([@bib53]). In this study, we characterized an overlooked mechanism of *CCND1* mRNA regulation. c-Myc induced-*LAST* cooperates with CNBP, by which *LAST* is guided to the 5' untranslated region of *CCND1* messenger RNA and thus stabilizes *CCND1* mRNA ([Figure 6H](#fig6){ref-type="fig"}). The detailed mechanism underlying this 5'end protection requires further characterization.

Normal growth control depends on the architecture of precise cell cycle control, and disturbing any component of this network could result in neoplastic growth and tumorigenesis. The G1/S transition is a major checkpoint in cell cycle progression, as it is a 'point of no return' beyond which cells are committed to dividing. Cyclin D1, along with its catalytically active partner CDK4, is a positive cell cycle regulator that advances the cell cycle from G1 to S phase ([@bib36]). Instead of protein factors, in this study, we found a novel long noncoding RNA, *LAST*, that ensures normal cell cycle progression. Lacking this lncRNA causes cell cycle arrest at the G1/S stage due to decreased cyclin D1 and attenuates tumor growth. Both the *LAST* and *CCND1* expression levels are higher in most tumor tissues than in their corresponding normal tissues ([Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}). Conceivably, *LAST* could be a potential target for new cancer therapeutics. However, a correlation between the expression levels of *CCND1* and *LAST* in the 15 tumor types examined was not found ([Supplementary file 4](#supp4){ref-type="supplementary-material"}). In addition, there was no difference in survival when tumors were divided into those expressing high versus low *CCND1* or *LAST*. These results imply that the regulation of *CCND1* is more complicated than we had anticipated, and new functions of *LAST* need to be characterized.

CNBP encodes a nucleic-acid binding protein that has seven zinc-finger domains and a preference for binding single-stranded DNA and RNA ([@bib17]). Previous studies have shown that CNBP acts on cap-independent translation of ornithine decarboxylase mRNA ([@bib48]) and also functions in sterol-mediated transcriptional regulation as well as c-Myc transcription ([@bib46]; [@bib37]). In this study, we found that CNBP possesses a new function. CNBP is able to guide lncRNA to bind to the 5'UTR of *CCND1* mRNA, acting as a mediator between *LAST* and *CCND1* mRNA.

lncRNAs are able to regulate their genomic neighborhoods in cis ([@bib45]). Examples of cis-acting lncRNAs include enhancer RNAs (eRNAs) ([@bib8]), imprinted lncRNAs ([@bib34]; [@bib52]) and dosage compensation lncRNAs ([@bib30]; [@bib7]). Homo sapiens *cyclin D1/CCND1* and *LAST* are both located on chromosome 11, and the two genes are 1.8 Mb apart and in the same transcriptional direction (+strand). It is interesting to note that although *CCND1* and *LAST* are both subjected to positive transcriptional regulation by c-Myc, they do not share the same promoter. Rather, *CCND1* and *LAST* are transcribed separately by c-Myc via their respective promoters ([Figures 1K](#fig1){ref-type="fig"} and [6H](#fig6){ref-type="fig"}). The relatively long distance between the *CCND1* and *LAST* genes may preclude their direct interaction. Moreover, *LAST* was shown to borrow a trans-acting factor, CNBP, as a mediator to connect the 5'UTR of *CCND1* mRNA and itself, thus affecting *CCND1/cyclin D1* expression in trans. Without CNBP, *LAST* shows no effect on CCND1 ([Figure 3---figure supplement 1F](#fig3s1){ref-type="fig"}), further supporting the concept that *LAST* does not regulate CCND1 in cis. Therefore, co-location of *CCND1* and *LAST* on the same chromosome appears to be a random event.

In summary, our findings from this investigation have uncovered a novel, c-Myc-induced, long non-coding RNA, *LAST*. The *LAST* gene is encoded physically on the same chromosome as *CCND1*. Normally, *LAST* interacts with CNBP, a RNA binding protein, by which it is guided towards the 5'UTR of *CCND1* mRNA, leading to the stabilization of *CCND1* mRNA, which in turn ensures orderly cell cycle progression. In the case of *LAST* dysregulation, *CCND1* mRNA becomes unstable, resulting in decreased cyclin D1, inevitably causing cell cycle arrest and stoppage of cell division ([Figure 6H](#fig6){ref-type="fig"}). This is a novel mechanism for *CCND1* mRNA regulation. Based on the importance of cyclin D1 in proliferative control and its ability to promote oncogenic transformation, this finding provides new insight into the complexity of the regulatory network underlying the mechanistic regulation of *cyclin D1/CCND1*. Moreover, this *LAST*/CNBP regulatory mode can be applied to other genes; three different mRNAs, *SOX9*, *NFE2L1* and *PDF,* were identified with half-lives that were prolonged by *LAST*/CNBP. The lack of similarity between human *LAST* and transcripts of *Mus musculus* also precludes using mouse c-Myc-driven tumor models to further clarify the significance of the *LAST* in c-Myc-mediated cell cycle regulation and tumor growth in vivo ([Figure 6I](#fig6){ref-type="fig"}).

Materials and methods {#s4}
=====================

Antibodies and reagents {#s4-1}
-----------------------

The following antibodies were used for western blot analysis in this study: anti-c-Myc (Cell Signaling Technology); anti-GAPDH and anti-β-Actin (CMC-TAG); normal rabbit IgG, normal mouse IgG~2a~, anti-HUR, anti-cyclin D1, anti-CNBP and anti-NADSYN1 (Santa Cruz); anti-FLAG (Sigma-Aldrich); anti-cyclin E1, anti-CDK2, and anti-CDK4 (ImmunoWay Biotechnology Company); anti-HNRNPK (ABclonal); anti-DHCR7 (ABCAM). Anti-c-Myc used for ChIP assay was from Santa Cruz. Thymidine, Nocodazole, Mimosine, EGF, hydrocortisone, Cholera Toxin, insulin and Doxycycline was from Sigma-Aldrich. Actinomycin D was from Solarbio. Strepavidin beads for RNA pull-down assay was from Invitrogen.

Cell culture {#s4-2}
------------

H1299, HCT116, IMR90, 293T and HAFF cell lines were cultured in DMEM (Dulbecco\'s modified Eagle\'s medium) medium containing 10% fetal bovine serum. P493-6 and MCF7 cell lines were cultured in RPMI medium 1640 containing 10% fetal bovine serum. MCF10A cell line were cultured in DMEM/F12 medium containing 5% horse serum, 20 μg/mL EGF, 0.5 μg/mL hydrocortisone, 100 ng/mL Cholera Toxin and 10 μg/mL insulin. P493-6 cells carrying a c-Myc tet-off system were provided by professor Ping Gao. All other cell lines were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). All cells were tested by STR profiling (GenePrint 10 System kit from Promega and AuthentiFiler PCR Amplification Kit from ThermoFisher) to authenticate the identity. All cells were tested for mycoplasma contamination by Cell Culture Contamination Detection Kit (ThermoFisher).

Western blotting, northern blotting and real-time RT-PCR {#s4-3}
--------------------------------------------------------

Western blotting, Northern blotting and real-time RT-PCR were performed as described previously ([@bib64]).

Colony-formation assay {#s4-4}
----------------------

HCT116 cells (1 × 10^3^) expressing control shRNA, lncRNA-52 shRNA-1,--2, lncRNA-51 shRNA-1 or −2 were cultured in a six-well plate. Ten days later, cells were fixed, stained with crystal violet and photographed.

Quantitationfor the expression levels of *LAST* {#s4-5}
-----------------------------------------------

The exact copy numbers of *LAST* transcripts per HAFF, IMR90, MCF10A, HCT116, MCF7 or H1299 cell were quantified by using quantitative real-time RT-PCR assay. In this assay, serially diluted RT-PCR products of *LAST* were used as templates to formulate standard curves, and the exact copies of *LAST* per cell were calculated accordingly.

ChIP assay {#s4-6}
----------

HCT116 cells were crosslinked with 1% formaldehyde for 10 min. The ChIP assay was performed by using anti-c-Myc antibody and the Pierce Agarose ChIP kit (ThermoScientific, USA) according to the manufacturer\'s instructions. Anti-Rabbit immunoglobulin G was used as a negative control. The bound DNA fragments were subjected to real-time PCR using the specific primers ([Table 1](#table1){ref-type="table"}).
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###### Oligomers used in this study

  Name                    Application            Sequence
  ----------------------- ---------------------- ------------------------------------------------------------
  qrt-lncRNA-5639-F       qRT-PCR                GACCTTGGGCTAGTTATTTTGTG
  qrt-lncRNA-5639-R       qRT-PCR                TCCTCTCTCCTTTCCTGTCTG
  qrt-lncRNA-51-F         qRT-PCR                ACCACAGATCCAGTAGCCTAG
  qrt-lncRNA-51-R         qRT-PCR                CCTAACCACACTCCAAGACAC
  qrt-lncRNA-5630-F       qRT-PCR                CTCCAACATCACCAAAACCAC
  qrt-lncRNA-5630-R       qRT-PCR                TCTTGGCATGTGGTATCTGTC
  qrt-lncRNA-5690-F       qRT-PCR                TCGACATGAAACTTGGGTGG
  qrt-lncRNA-5690-R       qRT-PCR                GGCCAAATTCACTTGATGCTC
  qrt-LAST-F              qRT-PCR                GGATCCTCCATAAACGATCAG
  qrt-LAST-R              qRT-PCR                AGCTGGTCGGTGGTCTCTTA
  qrt-CNBP-F              qRT-PCR                CCTCGGATAGAGGTTTCCAG
  qrt-CNBP -R             qRT-PCR                ACCGCAGTTATAGCAGGCTT
  qrt-CDK4-F              qRT-PCR                CTGGTGTTTGAGCATGTAGACC
  qrt-CDK4-R              qRT-PCR                AAACTGGCGCATCAGATCCTT
  qrt-CDK2-F              RT-PCR                 GCTAGCAGACTTTGGACTAGCCAG
   qrt-CDK2-R             qRT-PCR                AGCTCGGTACCACAGGGTCA
  qrt-CCNB1-F             qRT-PCR                AAGAGCTTTAAACTTTGGTCTGGG
  qrt-CCNB1-R             qRT-PCR                CTTTGTAAGTCCTTGATTTACCATG
  qrt-CCNE1-F             qRT-PCR                ATCAGCACTTTCTTGAGCAACA
  qrt-CCNE1-R             qRT-PCR                TTGTGCCAAGTAAAAGGTCTCC
  qrt-CCND1-CDS-F         qRT-PCR                ACGAAGGTCTGCGCGTGTT
  qrt-CCND1-CDS-R         qRT-PCR                CCGCTGGCCATGAACTACCT
  qrt-CCND1-5'UTR-F       qRT-PCR                CTGGAGCCTCCAGAGGGCTGT
  qrt-CCND1-5'UTR-R       qRT-PCR                GCGCTCCCTCGCGCTCTTC
  qrt-CCND1-3'UTR-1-F     qRT-PCR                GGAAAGCTTCATTCTCCTTGTTG
  qrt-CCND1-3'UTR-1-R     qRT-PCR                TTCTTTTGCTTAAGTCAGAGATGGAA
  qrt-CCND1-3'UTR-2-F     RT-PCR                 CATTGATTCAGCCTGTTTGG
  qrt-CCND1-3'UTR-2-R     qRT-PCR                GAATTCATCGGAACCGAACT
  qrt-CCND1-3'UTR-3-F     RT-PCR                 TCTCAATGAAGCCAGCTCACA
  qrt-CCND1-3'UTR-3-R     RT-PCR                 TTTTGGTTCGGCAGCTTG
  qrt-CCND1-intron-1-F    qRT-PCR                CTTTGTTCAAGCAGCGAGTC
  qrt-CCND1-intron-1-R    qRT-PCR                AAGGTCCTCCAAGCCGATA
  qrt-CCND1-intron-2-F    qRT-PCR                CCCAGCTCCCTTGAGTCC
  qrt-CCND1-intron-2-R    qRT-PCR                CGGTCCTGGATGTTGGAG
  qrt-CCND1-intron-3-F    qRT-PCR                TTTGTCATCGGCCAGAAATA
  qrt-CCND1-intron-3-R    qRT-PCR                GACCTTCAGAGCACAGACCA
  qrt-CCND1-intron-4-F    qRT-PCR                ATGTGCGTGGCCAATAAATA
  qrt-CCND1-intron-4-R    qRT-PCR                ATCCCAGGGTTTAACAGCAG
  qrt-c-Myc-F             qRT-PCR                AGCGACTCTGAGGAGGAAC
  qrt-c-Myc-R             qRT-PCR                TGTGAGGAGGTTTGCTGTG
  qrt-PDF-F               qRT-PCR                GCTGCGGCGCTCCTATT
  qrt-PDF-R               qRT-PCR                TTGGCACACGTGCGAGAAC
  qrt-NFE2L1-F            qRT-PCR                TGGCTATGGTATCCACCCCA
  qrt-NFE2L1-R            qRT-PCR                ACCAGCCAGGCATTTACCTC
  qrt-SOX9-F              qRT-PCR                GCGAGCCCGATCTGAAGAAG
  qrt-SOX9-R              qRT-PCR                GTTCTTGCTGGAGCCGTTGA
  qrt-DHCR7-F             qRT-PCR                ATCTGCCATGACCACTTCGG
  qrt-DHCR7-R             qRT-PCR                CAGACCCTGCAGCGTGTAAA
  qrt-NADSYN1-F           qRT-PCR                GCCGTGAGGAGTGGAAATGA
  qrt-NADSYN1-R           qRT-PCR                GTGGTCAGTATGCGTCCACA
  qrt-TOMM6-F             qRT-PCR                TGCTGGCTCGGCTAATGAAA
  qrt-TOMM6-R             qRT-PCR                TCCTATCAGTGGCAAAGCGG
  qrt-CEBPG-F             qRT-PCR                GAGCATGCACACAACCTTGC
  qrt-CEBPG-R             qRT-PCR                CATTGTCGCCATCTGCTGTC
  qrt-PRNP-F              qRT-PCR                GGAGAACTTCACCGAGACCG
  qrt-PRNP-R              qRT-PCR                AGGACCATGCTCGATCCTCT
  qrt-CHMP1B-F            qRT-PCR                GTTCAACCTGAAGTTCGCGG
  qrt-CHMP1B-R            qRT-PCR                GGCATTTTCGGCGTGTATCC
  qrt-MSX1-F              qRT-PCR                CCACTCGGTGTCAAAGTGGA
  qrt-MSX1-R              qRT-PCR                GAAGGGGACACTTTGGGCTT
  qrt-THAP11-F            qRT-PCR                AACCTGGTATCTGCTTCCGC
  qrt-THAP11-R            qRT-PCR                TGAGATCGATGGGCTTCACG
  qrt-C16orf91-F          qRT-PCR                ATGGGAAAGGGACATCAGCG
  qrt-C16orf91-R          qRT-PCR                CTCCCCACACCTGTCTCAAC
  qrt-VMA21-F             qRT-PCR                CATCTGCACAGCACCTTACAGTTTGC
  qrt-VMA21-R             qRT-PCR                GAAATGCAGCACATCCAAATCCTCCC
  qrt-PLEC-F              qRT-PCR                CCGGGCAGTCTCTGAAGATG
  qrt-PLEC-R              qRT-PCR                GCGTTTTCCCAAGGTTCCAG
  qrt-DLG5-F              qRT-PCR                GATGACCCGGGAGAGAAACG
  qrt-DLG5-R              qRT-PCR                GGATTCAGCCTGTGGTAGGG
  qrt-EPPK1-F             qRT-PCR                GTGTGTGATGAGTGGCCACACC
  qrt-EPPK1-R             qRT-PCR                CTCTGGGTACACTGGCCTGCTCT
  qrt-HIST2H4A-F          qRT-PCR                GGCGGAAAAGGCTTAGGCAA
  qrt-HIST2H4A-R          qRT-PCR                CCAGAGATCCGCTTAACGCC
  qrt-MYH9-F              qRT-PCR                ATCTCGTGCTATCCGCCAAG
  qrt-MYH9-R              qRT-PCR                GTTGTACGGCTCCAACAGGA
  qrt-PPL-F               qRT-PCR                AGGCAAATACAGCCCCACTG
  qrt-PPL-R               qRT-PCR                AGGTCACTCTGCATCTTGGC
  qrt-PRKDC-F             qRT-PCR                GGACCTATAGCGTTGTGCCC
  qrt-PRKDC-R             qRT-PCR                GATCACTCAGGTAAGCCGCC
  qrt-GDF15-F             qRT-PCR                TCCAGATTCCGAGAGTTGCG
  qrt-GDF15-R             qRT-PCR                CGAGGTCGGTGTTCGAATCT
  qrt-Actin-F             qRT-PCR                GACCTGACTGACTACCTCATGAAGAT
  qrt-Actin-R             qRT-PCR                GTCACACTTCATGATGGAGTTGAAGG
  qrt-U6-F                qRT-PCR                GCTTCGGCAGCACATATACTAAAAT
  qrt-U6-R                qRT-PCR                CGCTTCACGAATTTGCGTGTCAT
  qrt-U1-F                qRT-PCR                GGCGAGGCTTATCCATTG
  qrt-U1-R                qRT-PCR                CCCACTACCACAAATTATGC
  sh-LAST-F-1             plasmid construction   ccggAAGAGGATCCTCCATAAACGActcgagTCGTTTATGGAGGATCCTCTTtttttg
  sh-LAST-R-1             plasmid construction   aattcaaaaaAAGAGGATCCTCCATAAACGActcgagTCGTTTATGGAGGATCCTCTT
  sh-LAST-F-2             plasmid construction   ccggTCAGCCATAGCAGCTGTGATTctcgagAATCACAGCTGCTATGGCTGAtttttg
  sh-LAST-R-2             plasmid construction   aattcaaaaaTCAGCCATAGCAGCTGTGATTctcgagAATCACAGCTGCTATGGCTGA
  sh-lncRNA-51-F-1        plasmid construction   ccggAAGCAGATGGAGGGAAGTTggatcc AACTTCCCTCCATCTGCTTtttttg
  sh-lncRNA-51-R-1        plasmid construction   aattcaaaaaAAGCAGATGGAGGGAAGTTggatccAACTTCCCTCCATCTGCTT
  sh-lncRNA-51-F-2        plasmid construction   ccggGGAAGCAGAGTAAGCAAGTGAGGATCCTCACTTGCTTACTCTGCTTCCtttttg
  sh-lncRNA-51-R-2        plasmid construction   aattcaaaaaGGAAGCAGAGTAAGCAAGTGAGGATCCTCACTTGCTTACTCTGCTTCC
  LAST-DNA-1-sense        lncRNA pull down       (biotin-)TAAACGATCAGCCATAGCA
  LAST-DNA-1-antisense    lncRNA pull down       (biotin-)TGCTATGGCTGATCGTTTA
  LAST-DNA-2-sense        lncRNA pull down       (biotin-)TCATCGTGCCTCAGTTTCC
  LAST-DNA-2-antisense    lncRNA pull down       (biotin-)GGAAACTGAGGCACGATGA
  LAST-DNA-3-sense        lncRNA pull down       (biotin-)ACAGACACAGTTCTTGGTC
  LAST-DNA-3-antisense    lncRNA pull down       (biotin-)GACCAAGAACTGTGTCTGT
  LAST-DNA-4-sense        lncRNA pull down       (biotin-)ATGGGTCATATATTACATG
  LAST-DNA-4-antisense    lncRNA pull down       (biotin-)CATGTAATATATGACCCAT
  LAST-DNA-5-sense        lncRNA pull down       (biotin-)GTTGAATATGTATGTTTAG
  LAST-DNA-5-antisense    lncRNA pull down       (biotin-)CTAAACATACATATTCAAC
  LAST-DNA-6-sense        lncRNA pull down       (biotin-)CCAGCCTCAGACAGATGGC
  LAST-DNA-6-antisense    lncRNA pull down       (biotin-)GCCATCTGTCTGAGGCTGG
  CCND1-DNA-1-sense       mRNA pull down         (biotin-)GCGCAGTAGCAGCGAGCAGCA
  CCND1-DNA-1-antisense   mRNA pull down         (biotin-)TGCTGCTCGCTGCTACTGCGC
  CCND1-DNA-2-sense       mRNA pull down         (biotin-)CCGCTGGCCATGAACTACCTG
  CCND1-DNA-2-antisense   mRNA pull down         (biotin-)CAGGTAGTTCATGGCCAGCGG
  CCND1-DNA-3-sense       mRNA pull down         (biotin-)AACACGCGCAGACCTTCGTTG
  CCND1-DNA-3-antisense   mRNA pull down         (biotin-)CAACGAAGGTCTGCGCGTGTT
  CCND1-DNA-4-sense       mRNA pull down         (biotin-)CGTAGGTAGATGTGTAACCTCT
  CCND1-DNA-4-antisense   mRNA pull down         (biotin-)AGAGGTTACACATCTACCTACG
  CCND1-DNA-5-sense       mRNA pull down         (biotin-)AGAGTCATCTGATTGGACAGGC
  CCND1-DNA-5-antisense   mRNA pull down         (biotin-GCCTGTCCAATCAGATGACTCT
  CCND1-DNA-6-sense       mRNA pull down         (biotin-)AATGAAGCCAGCTCACAGTGCT
  CCND1-DNA-6-antisense   mRNA pull down         (biotin-)AGCACTGTGAGCTGGCTTCATT
  ChIP-LAST-a-F           qRT-PCR for ChIP       TTCCTGACAGCAGATTCCAG
  ChIP-LAST-a-R           qRT-PCR for ChIP       TCTGCCATGTTTGGAGAATG
  ChIP-LAST-b-F           qRT-PCR for ChIP       ACCTGCTCACCTGGGCAAGC
  ChIP-LAST-b-R           qRT-PCR for ChIP       GGCAATCGCTGACATCATCCGGG
  ChIP-LAST-c-F           qRT-PCR for ChIP       GGGATCCCAGCTGACCAGCTG
  ChIP-LAST-c-R           qRT-PCR for ChIP       GAGGCACGATGATCCAGGTGATGAG
  ChIP-LAST-d-F           qRT-PCR for ChIP       CTGAGCCACAGTGCGAGCCG
  ChIP-LAST-d-R           qRT-PCR for ChIP       GACAGTAAGGCCTGTTACCCGAGC
  ChIP-LAST-e-F           qRT-PCR for ChIP       AAGTCAAACAGCACGAACCC
  ChIP-LAST-e-R           qRT-PCR for ChIP       CGGATGGGCATTGACGTTAT
  ChIP-LAST-f-F           qRT-PCR for ChIP       TCAAGTGCAGTTCCTGTAGTTTC
  ChIP-LAST-f-R           qRT-PCR for ChIP       GATGGCGCTGAATTCTTGGGAACC
  ChIP-LAST-g-F           qRT-PCR for ChIP       TCCCTTCTTGTCCCTTCAAA
  ChIP-LAST-g-R           qRT-PCR for ChIP       CCTAAAGACCAACGGGAAAC
  ChIP-LAST-h-F           qRT-PCR for ChIP       TCTAGGGTTCTGGGCTGTCT
  ChIP-LAST-h-R           qRT-PCR for ChIP       GTCAGGCTCACGAGACGAT

Luciferase reporter assay {#s4-7}
-------------------------

To determine the effect of c-Myc on *LAST* promoter, either p3xflag-Myc-CMV-24 or p3xflag-Myc-CMV-24-c-Myc was co-transfected into HCT116 cells together with individual pGL3, pGL3-BS2, pGL3-BS2M, pGL3-BS3 or pGL3-BS3M construct plus Renilla luciferase reporter plasmid. Twenty-four hours after transfection, firefly and Renilla luciferase activity were measured by a Dual-Luciferase Reporter Assay System (Promega, Madison, WI, USA). The data are represented as mean ± SD of three independent experiments.

Cell cycle analysis {#s4-8}
-------------------

HCT116 cells were infected with lentiviruses and screened by puromycin, followed by plating into 6 mm dishes. During the proliferative exponential phase (50% confluency), cells were fixed in 70% ethanol overnight. Cells were then stained with propidium iodide and analyzed by flow cytometry.

RNA in situ hybridization {#s4-9}
-------------------------

To detect *LAST*, RNA FISH was carried out as previously described with in vitro transcribed antisense probes labeled by Nucleic Acid Labeling Kits (Life technologies, USA) with Alexa Fluor 488 ([@bib60]). The sequence of RNA probe was CGUCUUUUCAGGACACAAAGGCAUGCAGGUGCAUCAUCUCUCUCUAUUAACGGGUCAGCUGGUCGGCAUGGUCAGCUGGUCGGUGGUCUCUUAUUAGGAGAAAGUCACUGAAAUCAGUCUCUUGUCCAAUCACAGCUGCUAUGGCUGAUCGUUUAUGGAGGAUCCUCUUCGCCCCGGGACGUGAGCCCUAGGACCAAGAACUGUGUCUGUUUUGCUCCUUGCGGUGCACCGGCGCCUGGACAUACGCUCCAUCAAUGUGCGUCGCGAGCCGCUGAAGCCCCAUUUGCCGAGGGGGAAACUGAGGCACGAUG. The nuclei were counterstained with PI.

Cytosolic/nuclear fractionation {#s4-10}
-------------------------------

HCT116 cells (1 × 10^7^) were incubated with hypotonic buffer (25 mM Tris-HCl, PH 7.4, 1 mM MgCl~2~, 5 mM KCl) on ice for 5 min. An equal volume of hypotonic buffer containing 1% NP-40 was then added, and each sample was left on ice for another 5 min. After centrifugation at 5000 g for 5 min, the supernatant was collected as the cytosolic fraction. The pellets were re-suspended in nucleus resuspension buffer (20 mM HEPES, PH 7.9, 400 mM NaCl~2~, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 1 mM PMSF), and incubated at 4°C for 30 min. Nuclear fraction was collected after removing insoluble membrane debris by centrifugation at 12000 g for 10 min.

RNA immunoprecipitation RT-PCR {#s4-11}
------------------------------

RNA immunoprecipitation (RIP) was performed as described previously ([@bib59]). 1 × 10^7^ cells were lysed in RIP buffer supplemented with RNase A inhibitor and DNase I before centrifugation. Cell lysates were precleared with protein A/G beads (Pierce) before they were incubated with protein A/G beads coated with the indicated antibodies at 4°C for 3 hr. After extensive washing, the bead-bound immunocomplexes were eluted using elution buffer (50 mM Tris \[pH 8.0\], 1% SDS, and 10 mM EDTA) at 65°C for 10 min. To isolate protein-associated RNAs from the eluted immunocomplexes, samples were treated with proteinase K, and RNAs were extracted by phenol/chloroform. Purified RNAs were then subjected to RT-PCR analysis.

RIP-seq (RIP sequencing) {#s4-12}
------------------------

RIP was performed as described previously ([@bib58]). Briefly, two 10 cm^2^ dishes of HCT116 cells were washed three times with cold PBS and irradiated at 200 mJ/cm^2^ at 254 nm in HL-2000 HybriLinker^TM^ UV Crosslinker. Cells were collected and resuspended in 1 ml RIP buffer. Cells were then homogenized and followed by 3 rounds of sonication on ice. Cell lysates were precleared with protein A/G beads (Pierce) before they were incubated with protein A/G beads coated with the indicated antibodies at 4°C for 3 hr. After extensive washing, the bead-bound immunocomplexes were eluted using elution buffer (50 mM Tris \[pH 8.0\], 1% SDS, and 10 mM EDTA) at 65°C for 10 min. To isolate protein-associated RNAs from the eluted immunocomplexes, samples were treated with proteinase K, and RNAs were extracted by phenol/chloroform. The sequencing was performed and analyzed by KangChen Bio-tech, Shanghai, China. The sequencing data were deposited in the National Center for Biotechnology Information Gene Expression Omnibus database (GSE106918).

mRNA-seq (mRNA sequencing) {#s4-13}
--------------------------

Total RNA from HCT116 cells expressing either control shRNA or *LAST* shRNA-1 was extracted by phenol/chloroform. The mRNA-seq was performed and analyzed by KangChen Bio-tech, Shanghai, China. The sequencing data were deposited in the National Center for Biotechnology Information Gene Expression Omnibus database (GSE106917).

G-rich motifs analysis in RIP sequencing data {#s4-14}
---------------------------------------------

The peak-calling tool MACS2 ([@bib63]) (<https://github.com/taoliu/MACS/>) with default parameter settings was used to call enriched peaks with *RIP.bed* as input and *input.bed* as control. A PERL script was written to calculate the proportion of the peaks containing each of the five given motifs (TGGAGNW, TGGAG, GGAGNW, GGAG and GGR) in all the RIP peaks. To test the significance of G-rich motif enrichment, another PERL script was used to perform statistical simulations by generating 1000 random samples of DNA sequences with the same size and the same length distribution as that of the RIP peaks. For each given motif, the average proportion (with standard deviation) of motif-containing sequences in random samples was calculated. A U-test was performed for each G-rich motif to test the significance of the difference between the proportion of the motif-containing sequences in RIP peaks and that in random DNA samples.

Biotin pull-down assay {#s4-15}
----------------------

All processes were performed in the RNase-free conditions. For antisense oligomer affinity pull-down assay, sense or antisense biotin-labeled DNA oligomers corresponding to *LAST* or *CCND1* mRNA (1 μM) were incubated with lysates from HCT116 cells (1 × 10^7^) or the cytosolic/nuclear extracts. One hour after incubation, streptavidin-coupled agarose beads (Invitrogen) were added to isolate the RNA-protein complex or RNA-RNA complex. For in vitro RNA pull-down assay, 5 μg in vitro-synthesized biotin-labeled RNA was incubated with lysates from HCT116 cells (1 × 10^7^) for 3 hr. Streptavidin-coupled agarose beads (Invitrogen) were then added to the reaction mix to isolate the RNA-protein complex or RNA-RNA complex. Immunocomplexes were then analyzed by real-time RT-PCR or western blotting.

Electrophoretic mobility shift assay {#s4-16}
------------------------------------

The electrophoretic mobility shift assay (EMSA) was performed by using an EMSA/gel shift kit (Beyotime, China). Flag-CNBP protein was purified from 293T cells expressing Flag-CNBP. The biotin-labeled RNA fragments (as shown in [Figure 4D and E](#fig4){ref-type="fig"}) in vitro transcribed by T7 Transcription Kit (Epicentre, USA) were used in EMSA.

Xenograft mouse model {#s4-17}
---------------------

HCT116 cells expressing control RNA or *LAST* (3 × 10^6^) were subcutaneously injected into the dorsal flank of 4-week-old male athymic nude mice (Shanghai SLAC Laboratory Animal Co. Ltd.) (n = 7 mice per group). After 3 weeks, mice were sacrificed, and tumors were excised and weighed. HCT116 cells expressing control shRNA or *LAST* shRNA-1 (3 × 10^6^) were subcutaneously injected into the dorsal flank of 4-week-old male athymic nude mice (Shanghai SLAC Laboratory Animal Co. Ltd.) (n = 7 mice per group). After 6 weeks, mice were sacrificed, and tumors were excised and weighed. Mice were randomly assigned to different experimental groups. During testing the tumors\' weight, the experimentalists were blinded to the information and shape of tumor tissue masses. Studies on animals were conducted with approval from the Animal Research Ethics Committee of the University of Science and Technology of China (Permit Number: USTCACUC1701003).
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###### Overlap of the CNBP RIP sequencing dataset and *LAST* knockdown mRNA sequencing dataset (downregulation).

Information of *SOX9*, *PDF*, *NFE2L1* and *CCND1* is colored.
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###### *LAST* knockdown mRNA sequencing dataset (downregulation).
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###### Correlation between *LAST* and *CCND1* expression levels in fifteen TCGA tumor types.
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Major datasets {#s7}
--------------

The following datasets were generated:

Wu MZhang PCao L2017Myc regulates gene expression in P493-6 cell lines which carry a Myc tet-off system<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE106916>Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE106916)

Wu MCao LZhang P2017The impact of lncRNA LAST knockdown on gene expression profile in HCT116 cells<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE106917>Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE106917)

Wu MCao LZhang P2017Identification of CNBP binding mRNA and the binding sites/motifs in HCT116 cells<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE106918>Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE106918)

The following previously published datasets were used:

The Cancer Genome Atlas Research NetworkWeinstein JNCollisson EAMills GBMills Shaw KROzenberger BAEllrott KShmulevich ISander CStuart JM2013The Cancer Genome Atlas<https://cancergenome.nih.gov/>The National Cancer Institute (NCI) provides access to all individuals seeking information on www.cancer.gov, including individuals who are disabled. To provide this information, the NCI website complies with Section 508 of the Rehabilitation Act (as amended).

Mathelier AFornes OArenillas DJChen CDenay GLees JShai WShyr CTan GWorsley-Hunt RZhang AWParcy FLenhard BSandelin AWasserman WW2016The high-quality transcription factor binding profile database (JASPAR)<http://jaspar.genereg.net/>The database is ready to be deployed quickly for genome-wide studies through the JASPAR API.

Finn RDAttwood TKBabbitt PCBateman ABork PBridge AJChang HDosztanyi ZEl-Gebali SFraser MGough JHaft DHolliday GLHuang HHuang XLetunic ILopez RLu SMarchler-Bauer AMi HMistry JNatale DANecci MNuka GOrengo CAPark YPesseat SPiovesan DPotter SCRawlings NDRedaschi NRichardson LRivoire CSangrador-Vegas ASigrist CSillitoe ISmithers BSquizzato SSutton GThanki NThomas PDTosatto SCEWu CHXenarios IYeh LYoung SMitchell AL2009InterPro: protein sequence analysis & classification<http://www.ebi.ac.uk/interpro/>New SOAP-based Web Services have been added to complement the existing InterProScan Web Service. These allow users to programmatically retrieve InterPro entry data such as the abstract, integrated signature lists or GO terms. Users can download a range of clients from http://www.ebi.ac.uk/Tools/webservices/clients/dbfetch, including PERL, C\#.NET and Java clients, to access this data.

ENCODE Project Consortium2004Encyclopedia of DNA Elements<https://www.encodeproject.org/>Publicly available at ENCODE
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"LncRNA-CCND1, a c-Myc-inducible long noncoding RNA, cooperates with CNBP to promote CCND1 mRNA stability\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors and the evaluation has been overseen by Naama Barkai as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

In this manuscript Cao and colleagues describe the function of a lncRNA that they name lncRNA-CCDN1. It is transcriptionally regulated by c-Myc and necessary for cell cycle progression. The authors found that lncRNA-CCDN1 promotes the stability of CCDN1 mRNA by binding to it through the protein CNBP. They finally show that lncRNA-CCDN1 is upregulated in some cancers, and its downregulation inhibits tumor growth in xenografts.

The authors make a quite convincing case for the claim that lncRNA-CCND1 post-transcriptionally regulates the accumulation in the cytoplasm of the CCND1 RNA. The experiments are performed overall to a high standard, and since there are few convincing reports of lncRNAs regulating mRNA stability in the cytoplasm, this study is of high interest to the lncRNA community and the broader audience interested in gene regulation. However, some aspects need clarification and improvement prior to decision on publication.

Essential revisions:

1\) The name of the lncRNA is not appropriate. Since the authors show that exogenous over-expression of lncRNA-CCND1 is sufficient for regulation of CCND1, and a rescue experiment with shRNA-insensitive lncRNA-CCND1, this lncRNA appears to act in trans. Therefore, the localization of lncRNA-CCND1 and CCND1 on the same chromosome is inconsequential, and since there is no evidence for direct pairing between the two RNA molecules, it's also not clear that CCND1 is the main target of lncRNA-CCND1. There is no justification for the lncRNA-CCND1 name and the authors should choose a more appropriate one.

2\) The authors should check the effect of the shRNA knockdown of lncRNA-CCND1 on the two adjacent genes DHCR7 and NADSYN1.

3\) Because the sequence of the lncRNA is composed mostly of transposable elements, there is a concern about the specificity of the FISH probe, which does not appear to be listed in the supplementary materials. The authors should provide the sequence and show specificity of the signal using their shRNA KD cells, and to also show that the RNA is cytoplasmic in their subcellular fractionation data.

4\) The TCGA analysis is lacking -- its currently showing data from just two tumor types. They authors should show a comparison of normal and tumor expression levels for lncRNA-CCND1 in all the solid tumors in which TCGA has data (\~15 tumor types), and show the same comparison for CCND1 levels, as well as the correlation between CCND1, MYC and lncRNA-CCND1 expression levels in each tumor type. If tumors are divided into those expressing high versus low cyclin D1 or lncRNA-CCND1, is there a difference in survival (Kaplan Meier plots).

5\) The authors show some CLIP-seq data in [Figure 5](#fig5){ref-type="fig"}, but it's not described at all and not used in the rest of the study. They should describe in detail how these data were obtained and what is their quality. Do they see CLIP peaks on CCND1 and lncRNA-CCND1? Do they see G-rich motifs in the CLIP peaks when considering the whole transcriptome? If the data is not of proper quality, it is best to leave it out of the manuscript.

6\) The analysis of the transcripts that are both bound by CNBP and changed upon lincRNA KD should be part of the results and not the discussion. This part of the analysis is incomplete and the conclusions are not fully supported by the data. Is the overlap significantly higher than expected by chance? How many of the 10 mRNAs have different half-lifes following lincRNA-CCND1 KD and overexpression? Without these data the claim that this lincRNA can regulate other transcripts in the same way is not supported.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"LAST, a c-Myc-inducible long noncoding RNA, cooperates with CNBP to promote CCND1 mRNA stability in human cells\" for further consideration at *eLife*. Your revised article has been favorably evaluated by Naama Barkai (Senior editor), a Reviewing editor, and two reviewers.

The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:

Major comments:

1\) It is not clear how the RIP-seq experiment was done -- the authors refer to Yang et al., (2014), but it has RIP qRT-PCR and not RIP-seq. It is not clear if any digestion of the RNA following IP is performed. If there is no digestion -- how can the authors conclude from it where CNBP is binding the CCND1 mRNA? If there is no digestion, then the peaks merely correspond to regions that are resistant to degradation, and it's not surprising that they G/C-rich.

2\) The manuscript still needs very extensive language editing. Sentences like \"In addition, c-Myc has been reported to repress transcription of CCND1 mediated by core elements of the CCND1 promoter but not MAX when expression of human Myc in BALB/c-3T3 cells, Rat6 cells and rat embryo fibroblasts.\" (from the Introduction) are not comprehendible. Other examples: \"was particularly attracted our attention\", \"G1-relevant cyclins and CDKs genes\", \"To further confirm that LAST affect CCND1 mRNA stability is through CNBP\", \"It is therefore expected that knockdown of CNBP will reduced the association between LAST and CCND1 mRNA\", \"The exact reason for LAST or 5-\'UTR involved in choosing the CNBP domain(s) for association is not clear at this moment\", \"Three mRNAs namely *SOX9, NFE2L1* and *PDF* as the same as CCND1\", \"Six weeks after cells expressing shRNA injection or three weeks after cells expressing lncRNA injection, Due to the humane care for experimental animals,\". These are just some of the examples. In present form, the article cannot be published in *eLife* without editing.

3\) The lack of any anti-correlation between CCND1 and LAST across tumor samples, which should be discussed in the manuscript. It's negative data, but important negative data, and so cannot be left out.

4\) We cannot find the accession number for the mRNA-seq, microarray and RIP-seq results in the manuscript. Was the raw data deposited?

10.7554/eLife.30433.050

Author response

> Essential revisions:
>
> 1\) The name of the lncRNA is not appropriate. Since the authors show that exogenous over-expression of lncRNA-CCND1 is sufficient for regulation of CCND1, and a rescue experiment with shRNA-insensitive lncRNA-CCND1, this lncRNA appears to act in trans. Therefore, the localization of lncRNA-CCND1 and CCND1 on the same chromosome is inconsequential, and since there is no evidence for direct pairing between the two RNA molecules, it's also not clear that CCND1 is the main target of lncRNA-CCND1. There is no justification for the lncRNA-CCND1 name and the authors should choose a more appropriate one.

We agree that name of this lncRNA in previous manuscript is not very appropriate. Besides CCND1 mRNA, we showed in this revised manuscript that this lncRNA is able to stabilize at least three additional mRNA transcripts, including *SOX9, NFE2L1* and *PDF* ([Figure 5C and 5D](#fig5){ref-type="fig"}). We therefore renamed this lncRNA as LAST ([L]{.ul}ncRNA-[A]{.ul}ssisted [S]{.ul}tabilization of [T]{.ul}ranscript). Literally, it means this lncRNA makes transcript last longer. Accordingly, sentences have been added in text to state this (subsection "Identification of LAST, a c-Myc responsive long noncoding RNA that promotes cell proliferation").

> 2\) The authors should check the effect of the shRNA knockdown of lncRNA-CCND1 on the two adjacent genes DHCR7 and NADSYN1.

We have checked the effect of LAST knockdown on its two adjacent genes DHCR7 and NADSYN1, and found that LAST showed no effect on either mRNA or protein level of those two genes ([Figure 2---figure supplement 1C](#fig2s1){ref-type="fig"}). This also implies that the decrease inCCND1 mRNA by knockdown of LAST is not an off-target effect. We have added sentences in text (subsection "LAST promotes G1/S transition and upregulates cyclin D1/CCND1").

> 3\) Because the sequence of the lncRNA is composed mostly of transposable elements, there is a concern about the specificity of the FISH probe, which does not appear to be listed in the supplementary materials. The authors should provide the sequence and show specificity of the signal using their shRNA KD cells, and to also show that the RNA is cytoplasmic in their subcellular fractionation data.

According to the reviewers' suggestion, we have listed the FISH probe against LAST in the Materials and methods section (RNA in situ hybridization). Additionally, we performed a FISH experiment in H1299 cells expressing control shRNA, LAST shRNA-1 or -2 and found that the LAST signal intensity was markedly reduced in LAST depleted cells ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}). These data showed that this probe we used is specific for LAST. Furthermore, the cytosolic localization of LAST was also confirmed by a new sub-cellular fractionation experiment shown in [Figure 1G](#fig1){ref-type="fig"}. Sentences have been added in text to state this (subsection "Identification of LAST, a c-Myc responsive long noncoding RNA that promotes cell proliferation").

> 4\) The TCGA analysis is lacking -- its currently showing data from just two tumor types. They authors should show a comparison of normal and tumor expression levels for lncRNA-CCND1 in all the solid tumors in which TCGA has data (\~15 tumor types), and show the same comparison for CCND1 levels, as well as the correlation between CCND1, MYC and lncRNA-CCND1 expression levels in each tumor type. If tumors are divided into those expressing high versus low cyclin D1 or lncRNA-CCND1, is there a difference in survival (Kaplan Meier plots).

We have analyzed the LAST and CCND1expressionlevels in 15 types of normal and tumor tissues from TCGA. Both LAST and CCND1 expression levels were higher in the majority of tumor tissues relative to normal tissues ([Figure 6E, 6F](#fig6){ref-type="fig"}, [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"} and [Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}). Sentences have been added in text to state this (subsection "LASTpromotes tumorigenesis"). However, the correlation between CCND1, Myc and LAST expression levels in 15 types of tumor examined was not found (Data are shown in below Table R1). In addition, there is no difference in survival when tumors are divided into those expressing high versus low cyclin D1 or LAST. As these results do not add significantly to the main message, we have not included them in the revised manuscript.

TCGA Tumor TypesPearson Correlation Coefficient (LAST-CCND1)P valuePearson Correlation Coefficient (LAST-Myc)P valuePearson Correlation Coefficient (CCND1- Myc)P valueSample SizeBLCA0.0280.567-0.1050.034-0.080.107408BRCA0.11900.1180-0.0690.0231090CESC0.0890.122-0.0050.93-0.0440.445304CHOL-0.0880.610.0250.884-0.1870.27436COAD-0.1620.0010.18800.0730.119454ESCA0.3370-0.1320.0940.0210.788161HNSC0.0340.442-0.0680.131-0.0310.496499KIRC0.0080.8450.0370.3990.0910.037530LIHC-0.0470.366-0.0140.7830.0030.949371LUAD-0.0370.402-0.0610.169-0.0330.454513PAAD-0.0250.7450.0220.7720.1540.041177PRAD-0.0610.174-0.0480.29-0.0160.715495READ-0.27700.0720.3570.0630.422165STAD0.1670.0010.0730.1590.0450.384375UCEC0.0240.58-0.0240.584-0.0490.25543

BLCA (bladder urothelial carcinoma); BRCA (breast invasive carcinoma); CESC (cervical squamous cell carcinoma); CHOL (cholangiocarcinoma); COAD (colon adenocarcinoma); ESCA (esophageal carcinoma); HNSC (head and neck squamous carcinoma); KIRC (kidney renal clear cell carcinoma); LIHC (liver hepatocellular carcinoma); LUAD (lung adenocarcinoma); PAAD (pancreatic adenocarcinoma); PRAD (prostate adenocarcinoma); READ (rectum adenocarcinoma); STAD (stomach adenocarcinoma); UCEC (uterine corpus endometrial carcinoma).

> 5\) The authors show some CLIP-seq data in [Figure 5](#fig5){ref-type="fig"}, but it's not described at all and not used in the rest of the study. They should describe in detail how these data were obtained and what is their quality. Do they see CLIP peaks on CCND1 and lncRNA-CCND1? Do they see G-rich motifs in the CLIP peaks when considering the whole transcriptome? If the data is not of proper quality, it is best to leave it out of the manuscript.

We appreciate very much for referees' comment. We have analyzed the CNBP RIP-seq enrichment peaks and a *prominent* peak on CCND1 5'UTR was observed ([Figure 4---figure supplement 1C](#fig4s1){ref-type="fig"}). This is consistent with the conclusion from [Figure 4B](#fig4){ref-type="fig"}. Because the sequencing depth of CNBP RIP-seq is 6 G, it is not enough to analyze the peaks on noncoding RNA. However, we have evaluated the enrichment efficiency of LAST and CCND1 in the RIP-seq samples. Both LAST and CCND1 were significantly enriched by CNBP antibody ([Author response image 1](#respfig1){ref-type="fig"}). Furthermore, we checked the proportion of G-rich motifs in all peak sequences from CNBP RIP samples and found that nearly 60% of the CNBP enriched sequences contained GGAG core ([Figure 4---figure supplement 2B](#fig4s2){ref-type="fig"}), which is in good agreement with what had been previously reported (1, 2). These results prove that CNBP RIP-seq data are reliable. Sentences have been added in text to indicate these results (subsection "Both LAST and CCND1 mRNA bind to CNBP through their G-rich motifs").

![](elife-30433-resp-fig1){#respfig1}

> 6\) The analysis of the transcripts that are both bound by CNBP and changed upon lincRNA KD should be part of the results and not the discussion. This part of the analysis is incomplete and the conclusions are not fully supported by the data. Is the overlap significantly higher than expected by chance? How many of the 10 mRNAs have different half-lifes following lincRNA-CCND1 KD and overexpression? Without these data the claim that this lincRNA can regulate other transcripts in the same way is not supported.

In order to further analyze the data of mRNA-seq and RIP-seq, we examined half-lives of 75 genes in the overlap (CNBP enriched 4-fold above the control levels) in HCT116 cells expressing control shRNA or LAST shRNA-1. In addition to CCND1 mRNA, at least three additional mRNAs were identified to be regulated by LAST. Their half-lives are indeed changed following lincRNA-CCND1 KD and overexpression ([Figure 5C and 5D](#fig5){ref-type="fig"}). It suggests that CCND1 mRNA is not the only target regulated by LAST and CNBP. These data are now a part of the result in this revision (subsection "In addition to CCND1, LAST regulates the stabilization of some other mRNAs.").

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

> Major comments:
>
> 1\) It is not clear how the RIP-seq experiment was done -- the authors refer to Yang et al., (2014), but it has RIP qRT-PCR and not RIP-seq. It is not clear if any digestion of the RNA following IP is performed. If there is no digestion -- how can the authors conclude from it where CNBP is binding the CCND1 mRNA? If there is no digestion, then the peaks merely correspond to regions that are resistant to degradation, and it's not surprising that they G/C-rich.

Reviewer is right, we performed RIP qRT-PCR as described in Yang et al., 2014, and RIP-seq was performed as described in Xiang et al.,(2014). The detailed method for RIP-seq has been added in the text (subsection "RIP-seq (RIP sequencing)"). In the RIP-seq experiment, cells were homogenized and then underwent 3 rounds of sonication on ice to remove the fragments that were not bound to CNBP. This information has been described in the method of RIP-seq.

> 2\) The manuscript still needs very extensive language editing. Sentences like \"In addition, c-Myc has been reported to repress transcription of CCND1 mediated by core elements of the CCND1 promoter but not MAX when expression of human Myc in BALB/c-3T3 cells, Rat6 cells and rat embryo fibroblasts.\" (from the Introduction) are not comprehendible. Other examples: \"was particularly attracted our attention\", \"G1-relevant cyclins and CDKs genes\", \"To further confirm that LAST affect CCND1 mRNA stability is through CNBP\", \"It is therefore expected that knockdown of CNBP will reduced the association between LAST and CCND1 mRNA\", \"The exact reason for LAST or 5-\'UTR involved in choosing the CNBP domain(s) for association is not clear at this moment\", \"Three mRNAs namely SOX9, NFE2L1 and PDF as the same as CCND1\", \"Six weeks after cells expressing shRNA injection or three weeks after cells expressing lncRNA injection, Due to the humane care for experimental animals,\". These are just some of the examples. In present form, the article cannot be published in eLife without editing.

Sentences mentioned by the reviewer as some of the examples have been corrected (Introduction; subsection "Identification of LAST, a c-Myc-responsive long noncoding RNA that promotes cell proliferation"; subsection "LAST promotes G1/S transition and upregulates cyclin D1/CCND1"; subsection "LAST cooperates with CNBP to regulate CCND1mRNA stability"; subsection "Both LAST and CCND1 mRNA bind to CNBP through their G-rich motifs"; subsection "In addition to CCND1, LAST regulates the stability of other mRNAs."; subsection "LAST promotes tumorigenesis). Furthermore, we had our whole manuscript to be edited by English language editing service.

> 3\) The lack of any anti-correlation between CCND1 and LAST across tumor samples, which should be discussed in the manuscript. Its negative data, but important negative data, and so cannot be left out.

We have added these data in [Supplementary file 4](#supp4){ref-type="supplementary-material"}, and the description has been included in the Discussion section.

> 4\) We cannot find the accession number for the mRNA-seq, microarray and RIP-seq results in the manuscript. Was the raw data deposited?

We have uploaded the mRNA-seq, microarray and RIP-seq raw data to Gene Expression Omnibus (GEO). The accession numbers are provided in the text (subsections "Identification of LAST, a c-Myc-responsive long noncoding RNA that promotes cell proliferation", "RIP-seq (RIP sequencing)" and "mRNA-seq (mRNA sequencing)").

[^1]: These authors contributed equally to this work.
